| 鲍明亮,毕 清,田 青.埃克替尼二、三线治疗48例晚期非小细胞肺癌[J].中国肿瘤,2014,23(3):249-252. |
| 埃克替尼二、三线治疗48例晚期非小细胞肺癌 |
| Icotinib as Second or Third-line Treatment for ４８ cases with Advanced Non-small Cell Lung Cancer |
| 投稿时间：2013-10-15 |
| DOI：10.11735/j.issn.1004-0242.2014.03.A016 |
|
 |
| 中文关键词: 非小细胞肺癌 靶向治疗 EGFR-TKI 埃克替尼 |
| 英文关键词:non small cell lung cancer targeted therapy EGFR-TKI Icotinib |
| 基金项目: |
|
| 摘要点击次数: 2914 |
| 全文下载次数: 922 |
| 中文摘要: |
| 摘 要：［目的］ 探讨埃克替尼二、三线治疗非小细胞肺癌（NSCLC）的疗效及安全性。［方法］ 回顾性分析48例NSCLC患者的资料。治疗方法：埃克替尼片，口服，每次125mg，每日3次。分析患者的近期疗效及不良反应。［结果］ 治疗1个月后客观有效率（ORR）35.4%，疾病控制率（DCR）70.8%；治疗3个月后ORR 60.4%，DCR 79.2%；治疗6个月后ORR 45.8%，DCR 70.8%；治疗1年后ORR 27.1%，DCR 58.3%。对治疗3个月后不同临床特征患者的疗效分析显示，腺癌、无吸烟史及ECOG 2分是埃克替尼治疗获益的优势因素。不良反应主要是皮疹(47.9%)和腹泻(22.9%)。［结论］ 埃克替尼二、三线治疗晚期NSCLC具有较好的近期疗效及安全性。 |
| 英文摘要: |
| Abstract：［Purpose］ To evaluate the clinical efficacy and toxicities of Icotinib as second or third-line in the treatment for patients with advanced NSCLC patients. ［Methods］ The data of 48 cases with NSCLC were analyzed retrospectively. The patients were treated with Icotinib 125mg each time，3 times a day. The short-term effect and toxicities were analyzed. ［Results］ Efficacy evaluation：1 month after treatment，the objective response rate(ORR) was 35.4%，disease control rate(DCR) was 70.8%；3 months，ORR was 60.4%，DCR was 79.2%；6 months，ORR was 45.8%，DCR was 70.8%；and after 1 year，ORR was 27.1%，DCR was 58.3%.In different clinical features，the analysis showed that ORR (3 months after treatment) was positively related to the ECOG score 2，adenocarcinoma and non-smoking history. The main toxicities were rash (47.9%) and diarrhea (22.9%). ［Conclusion］ Icotinib as second or third-line in the treatment for NSCLC is effective and safe. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |